Resmed Taps Illumina Exec for Chief Investor Relations Officer Role

Resmed has appointed Salli Schwartz as its new chief investor relations officer, effective April 21. Schwartz will lead the company’s global investor relations and report to chairman and CEO Mick Farrell.

Schwartz touts over two decades of experience in finance roles at healthtech and financial services organizations. She joins Resmed from Illumina, where she was head of investor relations. In that role, she led investor engagement strategy, representing Illumina’s response to shareholder perspectives on corporate strategy, allocation of capital, and financial performance.

She was also a member of Illumina’s Corporate Social Responsibility Executive Steering Committee and its Transformation Office.

Before Illumina, Schwartz was head of investor relations and treasurer at MSCI Inc. There, she managed investor communications and a portfolio of over $2 billion in cash and short-term investments as well as over $4 million in high-yield debt. She was also a member of MSCI’s Corporate Responsibility Committee, Enterprise Risk Oversight Committee, and Investment Committee.

“Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” said Farrell. “Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”

Earlier in her career, Schwartz had many roles at Moody’s Corporation, including global head of strategic capital management and treasurer, and global head of investor relations and communications. She also worked in corporate strategy, corporate treasury, and FP&A with Citigroup.

“I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” said Schwartz. “I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”

Earlier this month, the company launched its NightOwl home sleep apnea test (HSAT) in the U.S.